Protein tyrosine phosphatase inhibitors
US11634417B2 · kind B2 · utility
0Cited by
0References
52Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 31, 2020 |
| Grant date | Apr 25, 2023 |
| Priority date | — |
| Expiry date | Mar 31, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.